Tuberculous meningitis (TBM) disables more than a third of its sufferers. Recent research has focused on optimizing the antitubercular regimen, mainly by increasing the dosage of rifampicin. However, pyrazinamide, with higher penetration into the central nervous system, is generally overlooked. We discuss the potential clinical impact of using pyrazinamide throughout antitubercular therapy in TBM, in contrast to only the intensive phase. This approach may improve the treatment outcomes and reduce disability in TBM. We summarize the available data regarding this approach from in vitro studies, clinical cohorts, toxicity data, and baseline resistance rates. Additionally, we discuss the two ongoing clinical trials evaluating this approach.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40121-024-01102-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Pyrazinamide Use: A Low-Hanging Fruit in Improving Outcomes with Tuberculous Meningitis? Narrative Review.
Infect Dis Ther
January 2025
Christian Medical College, Vellore, Tamil Nadu, India.
Tuberculous meningitis (TBM) disables more than a third of its sufferers. Recent research has focused on optimizing the antitubercular regimen, mainly by increasing the dosage of rifampicin. However, pyrazinamide, with higher penetration into the central nervous system, is generally overlooked.
View Article and Find Full Text PDFRisk Prediction Model for Isoniazid Dosing in Tuberculosis Meningitis Patients in Southwest China.
Int J Gen Med
December 2024
Department of Tuberculosis, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People's Republic of China.
Purpose: Tuberculosis meningitis (TBM) has emerged as the most lethal type of disease. The prognosis of meningitis is often related to disease severity and early therapeutic intervention.
Methods: Patients were screened for primary TBM and received a quadruple regimen comprising isoniazid (standard dose of 300 mg/day and high dose of 600 mg/day), rifampin, ethambutol, and pyrazinamide.
Therapeutic Strategies for Tuberculosis: Progress and Lessons Learned.
Biomed Environ Sci
November 2024
Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Article Synopsis
- * First-line treatments are being challenged by resistance, leading to the need for more toxic second-line drugs, but new agents and treatment regimens, like the BPaLM protocol, show promise for better efficacy and shorter treatment times.
- * Emerging strategies, including immunotherapy and cell therapies, aim to boost the immune response against TB, but significant obstacles remain in reaching the WHO's goal to end TB, especially due to resource diversion from the COVID-
Pyrazinamide-based Co(II), Ni(II) and Cu(II) complexes: DFT exploration of structure, reactivity properties and in silico ADMET profiles.
J Mol Model
November 2024
Department of Physics, Science Faculty, Ege University, Izmir, 35040, Turkey.
Context: In this paper, we present a theoretical study on the complexation of Co(II), Ni(II), and Cu(II) with a pyrazinamide ligand (PZA), which plays an important role in the treatment of tuberculosis and has biological and pharmacological benefits. It is a hybrid organic/inorganic material involving coordination between a metal ion and PZA ligand containing different coordination sites. This allows it to have different binding modes with metal ions and, therefore, provides a versatile ability to coordinate with metals.
View Article and Find Full Text PDFPerplexing paradoxical reactions: navigating the complexity of protracted tuberculosis meningitis-a case report.
Front Immunol
November 2024
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Tuberculous meningitis (TBM) has considerable mortality and morbidity, and it often presents therapeutic challenges when complicated by paradoxical reactions (PRs). Here, the clinical course of four cases of TBM patients complicated by PRs in a longitudinal TB cohort is described while also providing insights from the larger clinical cohort. Research flow cytometry, biomarker analysis, and drug concentrations were performed on available samples.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!